Method of detecting and evaluating angiotensinogen receptor-modulating compounds using placental cells

a technology of angiotensinogen receptor and placental cells, which is applied in the field of detecting and evaluating angiotensinogen receptormodulating compounds using placental cells, can solve the problems of inability to definitively answer the question whether agt is produced by placental tissue, the production of agt protein itself, and the identification of a renin-angiotensinogen receptor in native human placental cells
US7250265B2Inactive Publication Date: 2007-07-31MARSHFIELD CLINIC
1 Cites 1 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Patents(United States)
Current Assignee / Owner
MARSHFIELD CLINIC
Publication Date
2007-07-31
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Disclosed is a method of screening a substance for angiotensinogen receptor-modulatory activity. The method includes the steps of contacting placental-derived cells with labeled angiotensinogen and a candidate substance; and then determining whether the candidate substance inhibits the binding of angiotensinogen to the placental-derived cells relative to a control wherein the placental-derived cells are contacted with angiotensinogen in the absence of the candidate substance.
Need to check novelty before this filing date? Find Prior Art

Description

PRIORITY CLAIM

[0001] This is a National Phase application of PCT Application Serial No. PCT / US02 / 10932, filed 5 Apr. 2002 which claims priority to provisional patent application Ser. No. 60 / 282,082, filed 6 Apr. 2001, the entire contents of both are incorporated herein by reference.FIELD OF THE INVENTION

[0002] The invention is directed to the revelation of a placenta-specific renin-angiotensinogen receptor system in native human placental cells, and the use of cells exhibiting these newly-revealed receptors to assay putative drug candidates for their ability to modulate binding (reversibly, irreversibly, competitively, or non-competitively) at the placenta-specific renin-angiotensinogen receptor as it is displayed in native human placental cells.RELATED BACKGROUND

[0003] The renin-angiotensin (RA) system is an enzymatic cascade. The first (and rate-controlling) reaction is a renin-catalyzed cleavage of angiotensinogen (AGT) to yield the decapeptide angiotensin I (Ang I). The second step...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More